Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
EAST RUTHERFORD, N.J., Aug. 30, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that company management will present at the following investor conferences in September:
2017 Wells Fargo Healthcare Conference
Date: Wednesday, September 6, 2017
Time: 4:10 p.m. EDT
Location: Boston, MA
Baird’s 2017 Global Healthcare Conference
Date: Thursday, September 7, 2017
Time: 10:15 a.m. EDT
Location: New York, NY
The live audio webcasts and slide presentations can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and replays will be available for 90 days after the live events conclude.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201.804.3037 Email: [email protected]
